These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 18405171

  • 1. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension.
    Małyszko J, Tymcio J.
    Pol Arch Med Wewn; 2008; 118(1-2):36-41. PubMed ID: 18405171
    [Abstract] [Full Text] [Related]

  • 2. Thrombin activatable fibrinolysis inhibitor in hypertensive kidney transplant recipients.
    Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M.
    Transplant Proc; 2006; 38(1):105-7. PubMed ID: 16504676
    [Abstract] [Full Text] [Related]

  • 3. Markers of endothelial cell injury and thrombin activatable fibrinolysis inhibitor in nephrotic syndrome.
    Malyszko J, Malyszko JS, Mysliwiec M.
    Blood Coagul Fibrinolysis; 2002 Oct; 13(7):615-21. PubMed ID: 12439147
    [Abstract] [Full Text] [Related]

  • 4. A possible role of thrombin-activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients.
    Hryszko T, Malyszko J, Malyszko JS, Brzosko S, Pawlak K, Mysliwiec M.
    Nephrol Dial Transplant; 2001 Aug; 16(8):1692-6. PubMed ID: 11477176
    [Abstract] [Full Text] [Related]

  • 5. Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy.
    Małyszko J, Małyszko JS, Hryszko T, Myśliwiec M.
    Thromb Haemost; 2004 Mar; 91(3):480-6. PubMed ID: 14983223
    [Abstract] [Full Text] [Related]

  • 6. [Thrombin activatable fibrinolysis o inhibitor-TAFI- in dialyzed patients with diabetic nephropathy].
    Małyszko JS, Małyszko J, Hryszko T, Myśliwiec M.
    Pol Arch Med Wewn; 2003 Aug; 110(2):843-8. PubMed ID: 14682222
    [Abstract] [Full Text] [Related]

  • 7. A comprehensive study on hemostasis in CAPD patients treated with erythropoietin.
    Malyszko J, Suchowierska E, Malyszko JS, Mysliwiec M.
    Perit Dial Int; 2002 Aug; 22(5):582-92. PubMed ID: 12455569
    [Abstract] [Full Text] [Related]

  • 8. Comparison of effects of different heparins on thrombin activatable fibrinolysis inhibitor in hemodialyzed patients.
    Małyszko J, Małyszko JS, Hryszko T, Pawlak K, Myśliwiec M.
    Am J Nephrol; 2004 Aug; 24(6):624-9. PubMed ID: 15627717
    [Abstract] [Full Text] [Related]

  • 9. Some aspects of hemostasis in CAPD patients treated with erythropoietin.
    Małyszko J, Suchowierska E, Małyszko JS, Myśliwiec M.
    Kidney Blood Press Res; 2002 Aug; 25(4):240-4. PubMed ID: 12424426
    [Abstract] [Full Text] [Related]

  • 10. Thrombin-activatable fibrinolysis inhibitor in kidney transplant recipient with dyslipidemia.
    Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M.
    Transplant Proc; 2003 Sep; 35(6):2219-21. PubMed ID: 14529894
    [Abstract] [Full Text] [Related]

  • 11. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.
    Erem C, Ucuncu O, Yilmaz M, Kocak M, Nuhoglu I, Ersoz HO.
    Endocrine; 2009 Feb; 35(1):75-80. PubMed ID: 18958631
    [Abstract] [Full Text] [Related]

  • 12. Some aspects of hemostasis in kidney transplant recipients maintained on cyclosporine, azathioprine, and prednisone in comparison to patients treated with cyclosporine and prednisone.
    Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M.
    Transplant Proc; 2003 Dec; 35(8):2940-2. PubMed ID: 14697944
    [Abstract] [Full Text] [Related]

  • 13. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Chudý P, Kotuličová D, Staško J, Kubisz P.
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
    [Abstract] [Full Text] [Related]

  • 14. Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation.
    Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Nobori T, Shiku H.
    Thromb Res; 2001 Oct 01; 104(1):1-6. PubMed ID: 11583733
    [Abstract] [Full Text] [Related]

  • 15. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
    Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O, Onder Ersoz H.
    J Endocrinol Invest; 2009 Feb 01; 32(2):169-74. PubMed ID: 19411818
    [Abstract] [Full Text] [Related]

  • 16. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon.
    Binette TM, Taylor FB, Peer G, Bajzar L.
    Blood; 2007 Nov 01; 110(9):3168-75. PubMed ID: 17644733
    [Abstract] [Full Text] [Related]

  • 17. Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III-complex levels in patients with gastric cancer.
    Fidan E, Kavgaci H, Orem A, Yilmaz M, Yildiz B, Fidan S, Akcan B, Ozdemir F, Aydin F.
    Tumour Biol; 2012 Oct 01; 33(5):1519-25. PubMed ID: 22535370
    [Abstract] [Full Text] [Related]

  • 18. Thrombin-activatable fibrinolysis inhibitor in human abdominal aortic aneurysm disease.
    Bridge KI, Bollen L, Zhong J, Hesketh M, Macrae FL, Johnson A, Philippou H, Scott DJ, Gils A, Ariёns RAS.
    J Thromb Haemost; 2017 Nov 01; 15(11):2218-2225. PubMed ID: 28834317
    [Abstract] [Full Text] [Related]

  • 19. Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
    Antovic JP, Schulman S, An SS, Greenfield RS, Blombäck M.
    Scand J Clin Lab Invest; 2004 Nov 01; 64(8):745-51. PubMed ID: 15719893
    [Abstract] [Full Text] [Related]

  • 20. Identification of a thrombomodulin interaction site on thrombin-activatable fibrinolysis inhibitor that mediates accelerated activation by thrombin.
    Marar TT, Boffa MB.
    J Thromb Haemost; 2016 Apr 01; 14(4):772-83. PubMed ID: 26816270
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.